Navigation Links
Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness

l impaction that may require manual removal.

About Methylnaltrexone

Methylnaltrexone is an investigational drug that is being studied as a treatment for the peripheral side effects of opioid analgesics. It is designed to mitigate the effect of opioids on peripheral receptors without interfering with central nervous system pain relief. Methylnaltrexone is being developed in subcutaneous and oral forms to treat opioid-induced constipation and an intravenous form for the management of post-operative ileus (POI).

(PGNX-C)

About the Companies

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology as well as the treatment of human immunodeficiency virus (HIV) infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus.

In the area of HIV infection, the Company is developing the viral-entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the HIV co-receptor CCR5. Recently, the Company announced positive results from its phase 1b trial of PRO 140 in HIV-infected individuals. In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immunotherapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics also is developing vaccines designed to stimulate an immune response to PSMA and has a recombinant
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015  EP Global ... executives have recently contacted the Company about discussing ... as early as Monday, August 3, 2015.  Novartis ... as saying that the coming electronic contact lens ... dollars over the next several years.  Novartis partnered ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
(Date:7/31/2015)... Wilmington, DE (PRWEB) , ... July 31, 2015 ... ... long term care client base, with the recent implementation of Microsoft Dynamics GP ... provider in the industry, Intellitec is now supporting senior living communities in 16 ...
(Date:7/30/2015)... ... 31, 2015 , ... When responsible for the care of an aging loved ... through your mind: What happens if mom falls? Who will remind Dad to take ... plans. , But not taking time away from caregiving responsibilities can lead to bigger ...
(Date:7/30/2015)... ... July 31, 2015 , ... On July 22nd the Bradenton Herald ... plausible solutions for controlling the heroin outbreak. Ultimately the committee expressed lack of funding, ... perpetuating the heroin crisis in North Florida. The task force has proposed to instate ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards for ... published for use on the CDISC website . These three Therapeutic Area ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone Myers ... for women interested in improving their love lives using specific "lines" designed to ... to the public early this morning, has drawn praise from several dating and ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... Westchester, Ill. A study in the Feb. 1 issue ... impairments in older men with obstructive sleep apnea (OSA) are ... , A modest link between OSA severity and ... longer statistically significant after controlling for total sleep time. ...
... Researchers at Stanford University School of Medicine have identified ... Blocking the expression of the protein slowed or prevented ... vulnerable to the conditions of low oxygen that occur ... inhibiting the protein inhibits the tumor,s ability to grow," ...
... radiotherapy delivery systems cut dose, side effects after rare ... The best way to treat a rare form of ... by targeted radiotherapy, U.S. researchers say. , Ependymoma affects ... but concerns about side effects have limited the use ...
... Reported; No Other Products Within the NutriSystem Food Portfolio ... NutriSystem Inc., a leading provider of weight management products ... its NutriSystem-branded Peanut Butter Granola Bar due to the ... include all peanut products manufactured from January 1, 2007 ...
... of small arteries at the surface of the brain redirects ... to tissue starved of nutrients and oxygen following a stroke, ... optimistic news," said David Kleinfeld, a physics professor at the ... in animal models of stroke. , Damage from stroke can ...
... Officials with Baylor Health Care System ... the Baylor Research Institute (BRI) as vice ... 1. (Photo: http://www.newscom.com/cgi-bin/prnh/20090130/DC65143 )Under his leadership, ... of its unique research technologies in areas ...
Cached Medicine News:Health News:Daytime impairments in older men with obstructive sleep apnea are related to total sleep time 2Health News:Stanford study prevents pancreatic tumor growth in mice by inhibiting key protein 2Health News:Stanford study prevents pancreatic tumor growth in mice by inhibiting key protein 3Health News:Aggressive Treatment Effective in Kids' Brain Cancer 2Health News:NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 2Health News:NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 3Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2Health News:Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operating Officer 2Health News:Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operating Officer 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: